16.48
前日終値:
$16.94
開ける:
$16.85
24時間の取引高:
670.26K
Relative Volume:
0.61
時価総額:
$904.48M
収益:
$14.34M
当期純損益:
$-199.00M
株価収益率:
-4.2054
EPS:
-3.92
ネットキャッシュフロー:
$-183.51M
1週間 パフォーマンス:
-8.16%
1か月 パフォーマンス:
+15.28%
6か月 パフォーマンス:
+23.58%
1年 パフォーマンス:
+197.56%
Uniqure N V Stock (QURE) Company Profile
QURE を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
QURE
Uniqure N V
|
16.48 | 959.07M | 14.34M | -199.00M | -183.51M | -3.92 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-08-14 | アップグレード | Mizuho | Neutral → Outperform |
2025-04-01 | 再開されました | Chardan Capital Markets | Buy |
2024-12-10 | アップグレード | Raymond James | Outperform → Strong Buy |
2024-10-10 | 再開されました | Raymond James | Outperform |
2024-02-29 | ダウングレード | Goldman | Buy → Neutral |
2023-12-19 | ダウングレード | Mizuho | Buy → Neutral |
2022-03-17 | アップグレード | UBS | Neutral → Buy |
2021-06-15 | 開始されました | BTIG Research | Buy |
2021-05-21 | 開始されました | UBS | Neutral |
2021-04-26 | 再開されました | Credit Suisse | Outperform |
2021-04-01 | アップグレード | Mizuho | Neutral → Buy |
2021-01-07 | アップグレード | Guggenheim | Neutral → Buy |
2020-11-24 | 開始されました | H.C. Wainwright | Buy |
2020-11-11 | 開始されました | Berenberg | Buy |
2020-11-09 | 開始されました | Jefferies | Buy |
2020-11-04 | 開始されました | Cantor Fitzgerald | Overweight |
2020-10-23 | 開始されました | RBC Capital Mkts | Outperform |
2020-08-25 | 開始されました | Raymond James | Strong Buy |
2020-07-31 | アップグレード | Robert W. Baird | Neutral → Outperform |
2020-06-25 | ダウングレード | Mizuho | Buy → Neutral |
2020-06-25 | ダウングレード | Robert W. Baird | Outperform → Neutral |
2020-06-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
2019-12-03 | 開始されました | Cowen | Outperform |
2019-12-03 | 開始されました | Goldman | Buy |
2019-11-05 | 開始されました | Credit Suisse | Outperform |
2019-10-11 | 開始されました | Stifel | Buy |
2019-09-25 | 開始されました | Bernstein | Outperform |
2019-09-12 | 開始されました | Mizuho | Buy |
2019-07-30 | ダウングレード | Guggenheim | Buy → Neutral |
2019-07-08 | 繰り返されました | Cantor Fitzgerald | Overweight |
2019-04-12 | 開始されました | Piper Jaffray | Overweight |
2019-03-29 | 開始されました | Robert W. Baird | Outperform |
すべてを表示
Uniqure N V (QURE) 最新ニュース
Parkman Healthcare Partners LLC Sells 71,167 Shares of uniQure N.V. $QURE - MarketBeat
Huntington’s Disease Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Spark therapeutics, Chong Kun Dang Pharma, Neuvivo, UniQure Biopharma - Barchart.com
OMERS ADMINISTRATION Corp Takes $152,000 Position in uniQure N.V. $QURE - MarketBeat
Cubist Systematic Strategies LLC Makes New $2.56 Million Investment in uniQure N.V. $QURE - MarketBeat
uniQure (NASDAQ:QURE) Receives "Buy" Rating from Chardan Capital - MarketBeat
uniQure stock maintains Buy rating at H.C. Wainwright on promising Fabry data - Investing.com Nigeria
683 Capital Management LLC Boosts Stock Holdings in uniQure N.V. $QURE - MarketBeat
What does recent volatility data suggest for uniQure N.V.Market Growth Report & Real-Time Volume Analysis - Newser
Nantahala Capital Management LLC Has $29.21 Million Stock Holdings in uniQure N.V. $QURE - MarketBeat
uniQure reports positive initial data for Fabry disease gene therapy By Investing.com - Investing.com Nigeria
UniQure: Getting Nervous Ahead Of Critical Huntington's Gene Therapy Data (NASDAQ:QURE) - Seeking Alpha
Chart based analysis of uniQure N.V. trendsCEO Change & Daily Entry Point Alerts - Newser
uniQure Announces Initial AMT-191 Phase I/IIa Data Showing - GlobeNewswire
uniQure (QURE) Rating Reaffirmed with $70 Price Target by HC Wai - GuruFocus
uniQure's Investigational Gene Therapy Shows Promising Efficacy With Manageable Safety Risks For Fabry Disease - Benzinga
UniQure Says Early Data for Fabry Disease Gene Therapy Shows Promise - MarketScreener
Long term hold vs stop loss in uniQure N.V.Weekly Trade Report & High Yield Equity Trading Tips - Newser
uniQure reports positive initial data for Fabry disease gene therapy - Investing.com
uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease - Ariva
Is uniQure N.V. stock a top performer YTDJuly 2025 Spike Watch & Free Weekly Chart Analysis and Trade Guides - 더경남뉴스
Is uniQure N.V. exposed to political riskPortfolio Risk Summary & Smart Allocation Stock Reports - 더경남뉴스
uniQure N.V. stock chart pattern explainedJuly 2025 WrapUp & Community Trade Idea Sharing Platform - Newser
Using RSI to spot recovery in uniQure N.V.Index Update & Community Shared Stock Ideas - Newser
Rare Disease Therapy Approvals By FDA Speed Up Via New ProcessNeurogene (NASDAQ:NGNE) - Benzinga
Is uniQure N.V. stock overvalued or fairly pricedJuly 2025 Snapshot & Capital Efficient Trade Techniques - خودرو بانک
What indicators show strength in uniQure N.V.2025 Market Outlook & Free Risk Controlled Daily Trade Plans - Newser
Understanding uniQure N.V.’s price movementWeekly Earnings Recap & Low Drawdown Trading Techniques - Newser
What’s the RSI of uniQure N.V. stockJuly 2025 Movers & Low Risk Growth Stock Ideas - خودرو بانک
Visual analytics tools that track uniQure N.V. performanceQuarterly Portfolio Review & Weekly High Potential Alerts - Newser
Price action breakdown for uniQure N.V.2025 Valuation Update & High Conviction Buy Zone Alerts - Newser
What technical models suggest about uniQure N.V.’s comebackJuly 2025 Closing Moves & Daily Profit Maximizing Trade Tips - Newser
Is now a turning point for uniQure N.V.Wall Street Watch & Weekly Top Stock Performers List - Newser
Has uniQure N.V. formed a bullish divergenceJuly 2025 Levels & Precise Buy Zone Identification - Newser
Will a bounce in uniQure N.V. offer an exitMarket Activity Summary & Daily Momentum Trading Reports - Newser
Relative strength of uniQure N.V. in sector analysisJuly 2025 Analyst Calls & Daily Technical Stock Forecast Reports - Newser
Ranking uniQure N.V. among high performing stocks via tools2025 Key Lessons & Consistent Growth Equity Picks - Newser
Can uniQure N.V. rally from current levelsJuly 2025 Price Swings & Accurate Buy Signal Alerts - Newser
Using economic indicators to assess uniQure N.V. potential2025 Historical Comparison & Smart Investment Allocation Tips - Newser
Should I hold or sell uniQure N.V. nowJuly 2025 Pullbacks & Real-Time Volume Spike Alerts - خودرو بانک
Can uniQure N.V. outperform in the next rallyJuly 2025 Update & Long-Term Safe Investment Ideas - خودرو بانک
Using data tools to time your uniQure N.V. exitPortfolio Profit Report & Weekly Stock Performance Updates - Newser
Uniqure N V (QURE) 財務データ
収益
当期純利益
現金流量
EPS
Uniqure N V (QURE) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Springhorn Jeremy P. | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
37,694 |
POST LEONARD E | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
29,937 |
Kaye Jack | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
20,439 |
Jacques Rachelle Suzanne | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
28,346 |
Gut Robert | Director |
Jun 20 '25 |
Sale |
14.45 |
3,336 |
48,205 |
56,879 |
Balachandran Madhavan | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
37,697 |
Meek David D. | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
34,190 |
Potts Jeannette | Chief Legal Officer |
Jun 16 '25 |
Sale |
15.14 |
4,670 |
70,704 |
115,073 |
Kapusta Matthew C | CEO, Managing Director |
Mar 04 '25 |
Sale |
10.29 |
28,341 |
291,629 |
651,454 |
Abi-Saab Walid | Chief Medical Officer |
Mar 04 '25 |
Sale |
10.29 |
1,350 |
13,891 |
151,903 |
大文字化:
|
ボリューム (24 時間):